| scholarly article | Q13442814 |
| P50 | author | Shlomo Melmed | Q90044067 |
| Anat Ben-Shlomo | Q124638132 | ||
| Odelia Cooper | Q42659703 | ||
| P2093 | author name string | Hidenori Fukuoka | |
| Song-Guang Ren | |||
| Adam Mamelak | |||
| Dave Bruyette | |||
| P2860 | cites work | Tyrosine phosphorylation controls PCNA function through protein stability | Q24317732 |
| Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement | Q24629410 | ||
| NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene | Q24644235 | ||
| Acromegaly pathogenesis and treatment | Q24647360 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins | Q28210920 | ||
| Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors | Q29616203 | ||
| Mechanisms for pituitary tumorigenesis: the plastic pituitary | Q33630319 | ||
| Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis | Q33637242 | ||
| Review of epidermal growth factor receptor biology | Q34320636 | ||
| Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). | Q34381917 | ||
| A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice | Q34381923 | ||
| Retinoic acid as a novel medical therapy for Cushing's disease in dogs | Q34533079 | ||
| Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck | Q34563033 | ||
| HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. | Q34942996 | ||
| GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. | Q35001269 | ||
| Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor | Q35002806 | ||
| Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands | Q36813498 | ||
| Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery | Q37061261 | ||
| Heregulin regulates prolactinoma gene expression | Q37208143 | ||
| Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer | Q37282661 | ||
| Constitutive somatostatin receptor activity determines tonic pituitary cell response. | Q37302367 | ||
| Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved | Q37490013 | ||
| Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities | Q37592616 | ||
| Management of Cushing disease | Q37837501 | ||
| NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene | Q38346196 | ||
| Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells | Q38491249 | ||
| Mechanisms of resistance to ErbB-targeted cancer therapeutics | Q39242812 | ||
| Nuclear EGFR contributes to acquired resistance to cetuximab | Q39812008 | ||
| Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. | Q40344879 | ||
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway | Q40410769 | ||
| Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. | Q40467153 | ||
| Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. | Q40502745 | ||
| Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas | Q40564623 | ||
| The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. | Q40635170 | ||
| Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing | Q40736055 | ||
| Nuclear localization of EGF receptor and its potential new role as a transcription factor | Q40782527 | ||
| Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome | Q42462984 | ||
| Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways | Q44044835 | ||
| Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas | Q44179348 | ||
| Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. | Q46289012 | ||
| The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery | Q46289029 | ||
| Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia | Q48079288 | ||
| Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors | Q48089950 | ||
| Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas | Q48227723 | ||
| Epidermal growth factor rapidly stimulates prolactin gene transcription | Q48873674 | ||
| Hypophysectomy as a treatment for canine and feline Cushing's disease. | Q52129261 | ||
| Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. | Q54694108 | ||
| Cushing's syndrome | Q56228192 | ||
| Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging | Q68973952 | ||
| Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness | Q71091894 | ||
| Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors | Q73223967 | ||
| Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues | Q73714905 | ||
| Animal models of Cushing's disease | Q81067834 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4712-4721 | |
| P577 | publication date | 2011-11-21 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas | |
| P478 | volume | 121 |
| Q39449846 | A new medical therapy for Cushing disease? |
| Q90391968 | Advances in the medical treatment of Cushing's syndrome |
| Q38211375 | Aggressive pituitary adenomas--diagnosis and emerging treatments |
| Q58789954 | Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease |
| Q57470855 | Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas |
| Q39022297 | Currently used and investigational drugs for Cushing´s disease |
| Q35686067 | Cushing's disease: towards precision medicine |
| Q28262360 | Cushing's syndrome |
| Q38541695 | Cushing's syndrome: an update on current pharmacotherapy and future directions |
| Q35531889 | Cushing's syndrome: epidemiology and developments in disease management |
| Q33570330 | Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease |
| Q52738992 | EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis. |
| Q28547156 | Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis |
| Q93127216 | Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis |
| Q92210576 | Emerging and Novel Treatments for Pituitary Tumors |
| Q38605678 | Endocrinology research-reflecting on the past decade and looking to the next |
| Q34745279 | ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice |
| Q89510579 | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?" |
| Q91670265 | Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior |
| Q45204572 | Expression stability of reference genes for quantitative RT-PCR of healthy and diseased pituitary tissue samples varies between humans, mice, and dogs |
| Q36724063 | Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene |
| Q93063035 | Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies |
| Q58796556 | Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles |
| Q34240076 | Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. |
| Q48100826 | Genetic mechanisms of human hypertension and their implications for blood pressure physiology. |
| Q53683262 | Genetics of Cushing's Syndrome. |
| Q48162581 | Genetics of Cushing's disease. |
| Q38553643 | Genetics of Cushing's disease: an update |
| Q50646949 | Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease. |
| Q92582455 | Identification of microRNAs associated with the aggressiveness of prolactin pituitary tumors using bioinformatic analysis |
| Q58793747 | Identification of recurrent USP48 and BRAF mutations in Cushing's disease |
| Q58633992 | Imatinib Inhibits GH Secretion From Somatotropinomas |
| Q38950783 | Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells |
| Q41499785 | Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells |
| Q36231629 | Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas |
| Q33904619 | Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease |
| Q36184067 | Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics |
| Q38165863 | Molecular basis of pharmacological therapy in Cushing's disease |
| Q41716700 | Mutations in the deubiquitinase gene USP8 cause Cushing's disease |
| Q55249109 | New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A. |
| Q37049132 | New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy |
| Q38328843 | New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases |
| Q52674242 | Novel candidate genes important for asthma and hypertension comorbidity revealed from associative gene networks. |
| Q38755339 | Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro. |
| Q38715916 | POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells |
| Q48100949 | Pathogenesis of non-functioning pituitary adenomas |
| Q50060944 | Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. |
| Q38415507 | Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology |
| Q91558012 | Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us? |
| Q58616038 | Pituitary Gene Signalling Pathway |
| Q36716025 | Pituitary Medicine From Discovery to Patient-Focused Outcomes |
| Q38234756 | Pituitary side effects of old and new drugs |
| Q35154035 | Pituitary tumors |
| Q54961209 | Pituitary-Directed Therapies for Cushing's Disease. |
| Q33680681 | Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors |
| Q37651359 | Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas |
| Q90391041 | Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice |
| Q37621524 | Recent advances in the medical treatment of Cushing's disease |
| Q33632000 | Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations. |
| Q38112082 | Recent developments in drug therapy for Cushing's disease |
| Q35146226 | Recurrent gain-of-function USP8 mutations in Cushing's disease |
| Q52656860 | Role of the ubiquitin/proteasome system on ACTH turnover in rat corticotropes. |
| Q38777251 | Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside |
| Q37690499 | Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage |
| Q41057633 | Screening for GPR101 defects in pediatric pituitary corticotropinomas |
| Q90396537 | Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas |
| Q38785782 | Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease |
| Q92384606 | THYMIC CARCINOID WITH ADRENOCORTICOTROPIC HORMONE-PRODUCING ECTOPIC CUSHING SYNDROME AND EMPTY SELLA |
| Q33427688 | Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment |
| Q35813265 | The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease |
| Q47122908 | The Stem Cell Connection of Pituitary Tumors |
| Q27010590 | The Treatment of Cushing's Disease |
| Q92699881 | The Treatment of Refractory Pituitary Adenomas |
| Q37400088 | The genome-wide mutational landscape of pituitary adenomas. |
| Q38274982 | The role of genetic and epigenetic changes in pituitary tumorigenesis |
| Q30872897 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review |
| Q52806299 | USP8 Mutations in Pituitary Cushing Adenomas-Targeted Analysis by Next-Generation Sequencing. |
| Q43200816 | USP8 mutation in Cushing's disease |
| Q38545050 | USP8: a novel therapeutic target for Cushing's disease. |
| Q91679876 | Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing |
| Q92038158 | Ubiquitin-specific protease 8 (USP8/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions |
| Q33802284 | Update on medical treatment for Cushing's disease |
| Q34131012 | Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. |
| Q51571729 | mTOR promotes pituitary tumor development through activation of PTTG1. |
Search more.